Anti-Therapeutic Action: paranoia

A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics

mycolabadmin

Psychedelic compounds like psilocybin and ketamine show promise in treating serious mental health conditions including PTSD and depression. The FDA carefully evaluates these drugs through multi-phase clinical trials to ensure they are safe and effective. While California has proposed making psychedelics more widely available through legislation, the FDA’s thorough approval process provides important protections by identifying potential risks and ensuring proper medical oversight.

Read More »

Toxicology and Analysis of Psychoactive Tryptamines

mycolabadmin

Tryptamines are a growing class of psychoactive drugs that can cause hallucinations and other dramatic changes in perception. These substances, including compounds like DMT and psilocybin from magic mushrooms, work by affecting serotonin receptors in the brain. While some research explores their potential medical use for treating depression and anxiety, they also carry serious risks including dangerous changes in heart rate, body temperature, and mental state. Scientists have developed new laboratory methods to detect these drugs in blood and urine samples to help doctors diagnose and treat overdoses.

Read More »

Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon

mycolabadmin

Psilocybin, the active compound in certain mushrooms, shows promise as a treatment for depression and anxiety in cancer patients, particularly those nearing end of life. Oregon legalized supervised psilocybin therapy in 2020, making it the first U.S. state to do so. While clinical research shows the treatment can rapidly reduce depression and improve quality of life, the actual rollout has faced challenges including regulatory hurdles, lack of professional standards, and unequal geographic access.

Read More »
Scroll to Top